Exploratory clinical studies of a synthetic HIV-1 Tat epitope vaccine in asymptomatic treatment-naïve and antiretroviral-controlled HIV-1 infected subjects plus healthy uninfected subjects

Human Vaccines and Immunotherapeutics

Volumn 8, Issue 4, 2012, Pages 479-485

  Goldstein, Gideon ^a   Chicca, John J ^b  

^a Thymon LLC   (United States)

^b Molecular Diagnostic Services Inc   (United States)

Author keywords

Antiretroviral; Clinical trial; HIV 1; Human vaccine; Prophylactic; Tat; Therapeutic; TUTI 16

Indexed keywords

ADJUVANT; ANTIRETROVIRUS AGENT; CYTOKINE; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; MONOCLONAL ANTIBODY; PLACEBO; PROTEIN ANTIBODY; SYNTHETIC HIV 1 TAT EPITOPE VACCINE; TEPIUMAB; UNCLASSIFIED DRUG; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 TAT VACCINE;

ADULT; ANTIBODY RESPONSE; ARTICLE; ASYMPTOMATIC DISEASE; CD4 LYMPHOCYTE COUNT; CLINICAL ARTICLE; CLINICAL PROTOCOL; CLINICAL STUDY; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG SAFETY; FATIGUE; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; IMMUNOGENICITY; INFECTION CONTROL; INJECTION SITE ERYTHEMA; INJECTION SITE REACTION; LIMIT OF DETECTION; LYMPHOCYTE ACTIVATION; MALE; RANDOMIZED CONTROLLED TRIAL; VIREMIA; VIRUS LOAD; VIRUS REPLICATION; WEAKNESS; ACTIVE IMMUNIZATION; BLOOD; CONTROLLED CLINICAL TRIAL; DRUG TOXICITY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGY; ISOLATION AND PURIFICATION; METHODOLOGY; MIDDLE AGED; VIROLOGY;

ADULT; AIDS VACCINES; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DOUBLE-BLIND METHOD; DRUG TOXICITY; FEMALE; HIV ANTIBODIES; HIV INFECTIONS; HIV-1; HUMANS; IMMUNOTHERAPY, ACTIVE; MALE; MIDDLE AGED; VIRAL LOAD;

EID: 84860775852     PISSN: None     EISSN: 2164554X     Source Type: Journal    
DOI: 10.4161/hv.19184     Document Type: Article

References (35)

1. Ray M, Logan R, Sterne JA, Hernández-Díaz S, Robins JM, Sabin C, et al.; HIV-CAUSAL Collaboration. The effect of combined antiretroviral therapy on the overall mortality of HIV-infected individuals. AIDS 2010; 24:123-37; PMID:19770621; http://dx.doi.org/10.1097/QAD.0b013e3283324283.
2. Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, Kumarasamy N, et al.; HPTN 052 Study Team. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med 2011; 365:493-505; PMID:21767103; http://dx.doi.org/10.1056/NEJMoa1105243.
3. Trono D, Van Lint C, Rouzioux C, Verdin E, Barré-Sinoussi F, Chun TW, et al. HIV persistence and the prospect of long-term drug-free remissions for HIV-infected individuals. Science 2010; 329:174-80; PMID:20616270; http://dx.doi.org/10.1126/science.1191047.
4. Girard MP, Osmanov S, Assossou OM, Kieny MP. Human immunodeficiency virus (HIV) immunopathogenesis and vaccine development: a review. Vaccine 2011; 29:6191-218; PMID:21718747; http://dx.doi.org/10.1016/j.Vaccine.2011.06.085.
5. McMichael AJ, Borrow P, Tomaras GD, Goonetilleke N, Haynes BF. The immune response during acute HIV-1 infection: clues for vaccine development. Nat Rev Immunol 2010; 10:11-23; PMID:20010788; http://dx.doi.org/10.1038/nri2674.
6. Brumme ZL, Walker BD. Tracking the culprit: HIV-1 evolution and immune selection revealed by single-genome amplification. J Exp Med 2009; 206:1215-8; PMID:19487418; http://dx.doi.org/10.1084/jem.20091094.
7. Quinn TC, Wawer MJ, Sewankambo N, Serwadda D, Li C, Wabwire-Mangen F, et al.; Rakai Project Study Group. Viral load and heterosexual transmission of human immunodeficiency virus type 1. N Engl J Med 2000; 342:921-9; PMID:10738050; http://dx.doi.org/10.1056/NEJM200003303421303.
8. Royce RA, Seña A, Cates W Jr, Cohen MS. Sexual transmission of HIV. N Engl J Med 1997; 336:1072-8; PMID:9091805; http://dx.doi.org/10.1056/ NEJM199704103361507.
9. Mellors JW, Rinaldo CRJ Jr, Gupta P, White RM, Todd JA, Kingsley LA. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science 1996; 272:1167-70; PMID:8638160; http://dx.doi.org/10.1126/science.272. 5265.1167.
10. Goldstein G. HIV-1 Tat protein as a potential AIDS vaccine. Nat Med 1996; 2:960-4; PMID:8782444; http://dx.doi.org/10.1038/nm0996-960.
11. Chang HC, Samaniego F, Nair BC, Buonaguro L, Ensoli B. HIV-1 Tat protein exits from cells via a leaderless secretory pathway and binds to extracellular matrix-associated heparan sulfate proteoglycans through its basic region. AIDS 1997; 11:1421-31; PMID:9342064; http://dx.doi.org/10.1097/00002030-199712000- 00006.
12. Westendorp MO, Frank R, Ochsenbauer C, Stricker K, Dhein J, Walczak H, et al. Sensitization of T cells to CD95-mediated apoptosis by HIV-1 Tat and gp120. Nature 1995; 375:497-500; PMID:7539892; http://dx.doi.org/10.1038/375497a0.
13. Vendeville A, Rayne F, Bonhoure A, Bettache N, Montcourrier P, Beaumelle B. HIV-1 Tat enters T cells using coated pits before translocating from acidified endosomes and eliciting biological responses. Mol Biol Cell 2004; 15:2347-60; PMID:15020715; http://dx.doi.org/10.1091/mbc.E03-12-0921.
14. Li CJ, Ueda Y, Shi B, Borodyansky L, Huang L, Li YZ, et al. Tat protein induces self-perpetuating permissivity for productive HIV-1 infection. Proc Natl Acad Sci USA 1997; 94:8116-20; PMID:9223324; http://dx.doi.org/10.1073/pnas.94. 15.8116.
15. Sahaf B, Atkuri K, Heydari K, Malipatlolla M, Rappaport J, Regulier E, et al. Culturing of human peripheral blood cells reveals unsuspected lymphocyte responses relevant to HIV disease. Proc Natl Acad Sci USA 2008; 105:5111-6; PMID:18364393; http://dx.doi.org/10.1073/pnas.0712363105.
16. Goldstein G, Tribbick G, Manson K. Two B cell epitopes of HIV-1 Tat protein have limited antigenic polymorphism in geographically diverse HIV-1 strains. Vaccine 2001; 19:1738-46; PMID:11166899; http://dx.doi.org/10.1016/ S0264-410X(00)00393-5.
17. Ruckwardt TJ, Tikhonov I, Berg S, Hatfield GS, Chandra A, Chandra P, et al. Sequence variation within the dominant amino terminus epitope affects antibody binding and neutralization of human immunodeficiency virus type 1 Tat protein. J Virol 2004; 78:13190-6; PMID:15542671; http://dx.doi.org/10.1128/JVI. 78.23.13190-6.2004.
18. Goldstein G, Manson K, Tribbick G, Smith R. Minimization of chronic plasma viremia in rhesus macaques immunized with synthetic HIV-1 Tat peptides and infected with a chimeric simian/human immunodeficiency virus (SHIV33). Vaccine 2000; 18:2789-95; PMID:10812220; http://dx.doi.org/10.1016/S0264- 410X(00)00085-2.
19. Stacey AR, Norris PJ, Qin L, Haygreen EA, Taylor E, Heitman J, et al. Induction of a striking systemic cytokine cascade prior to peak viremia in acute human immunodeficiency virus type 1 infection, in contrast to more modest and delayed responses in acute hepatitis B and C virus infections. J Virol 2009; 83:3719-33; PMID:19176632; http://dx.doi.org/10.1128/JVI.01844-08.
20. Maggiorella MT, Baroncelli S, Michelini Z, Fanales-Belasio E, Moretti S, Sernicola L, et al. Long-term protection against SHIV89.6P replication in HIV-1 Tat vaccinated cynomolgus monkeys. Vaccine 2004; 22:3258-69; PMID:15308348; http://dx.doi.org/10.1016/j.Vaccine.2004.03.009.
21. Ensoli B, Fiorelli V, Ensoli F, Lazzarin A, Visintini R, Narciso P, et al. The preventive phase I trial with the HIV-1 Tat-based vaccine. Vaccine 2009; 28:371-8; PMID:19879233; http://dx.doi.org/10.1016/j.Vaccine.2009.10.038.
22. Longo O, Tripiciano A, Fiorelli V, Bellino S, Scoglio A, Collacchi B, et al. Phase I therapeutic trial of the HIV-1 Tat protein and long term follow-up. Vaccine 2009; 27:3306-12; PMID:19208456; http://dx.doi.org/10.1016/j.Vaccine. 2009.01.090.
23. Goldstein G, Chicca JJ, 2nd. A universal anti-HIV-1 Tat epitope vaccine that is fully synthetic and self-adjuvanting. Vaccine 2010; 28:1008-14; PMID:19931501; http://dx.doi.org/10.1016/j.Vaccine.2009.10.129.
24. Hübschle T, Mütze J, Mühlradt PF, Korte S, Gerstberger R, Roth J. Pyrexia, anorexia, adipsia and depressed motor activity in rats during systemic inflammation induced by the Toll-like receptors-2 and -6 agonists MALP-2 and FSL-1. Am J Physiol Regul Integr Comp Physiol 2006; 290:180-7; PMID:16154916; http://dx.doi.org/10.1152/ajpregu.00579.2005.
25. Okusawa T, Fujita M, Nakamura J, Into T, Yasuda M, Yoshimura A, et al. Relationship between structures and biological activities of mycoplasmaldiacylatedlipopeptides and their recognition by toll-like receptors 2 and 6. Infect Immun 2004; 72:1657-65; PMID:14977973; http://dx.doi.org/10.1128/ IAI.72.3.1657-65.2004.
26. Rodman TC, Pruslin FH, To SE, Winston R. Human immunodeficiency virus (HIV) Tat-reactive antibodies present in normal HIV-negative sera and depleted in HIV-positive sera. Identification of the epitope. J Exp Med 1992; 175:1247-53; PMID:1373758; http://dx.doi.org/10.1084/jem.175.5.1247.
27. thConference on retroviruses and opportunistic infections; paper #549; 2005; 2005.
28. Westendorp MO, Frank R, Ochsenbauer C, Stricker K, Dhein J, Walczak H, et al. Sensitization of T cells to CD95-mediated apoptosis by HIV-1 Tat and gp120. Nature 1995; 375:497-500; PMID:7539892; http://dx.doi.org/10.1038/375497a0.
29. Zeng W, Ghosh S, Lau YF, Brown LE, Jackson DC. Highly immunogenic and totally synthetic lipopeptides as self-adjuvantingimmunocontraceptive vaccines. J Immunol 2002; 169:4905-12; PMID:12391202.
30. Alphs HH, Gambhira R, Karanam B, Roberts JN, Jagu S, Schiller JT, et al. Protection against heterologous human papillomavirus challenge by a synthetic lipopeptide vaccine containing a broadly cross-neutralizing epitope of L2. Proc Natl Acad Sci USA 2008; 105:5850-5; PMID:18413606; http://dx.doi.org/10.1073/ pnas.0800868105.
31. Li CJ, Ueda Y, Shi B, Borodyansky L, Huang L, Li YZ, et al. Tat protein induces self-perpetuating permissivity for productive HIV-1 infection. Proc Natl Acad Sci USA 1997; 94:8116-20; PMID:9223324; http://dx.doi.org/10.1073/pnas.94. 15.8116.
32. Sahaf B, Atkuri K, Heydari K, Malipatlolla M, Rappaport J, Regulier E, et al. Culturing of human peripheral blood cells reveals unsuspected lymphocyte responses relevant to HIV disease. Proc Natl Acad Sci USA 2008; 105:5111-6; PMID:18364393; http://dx.doi.org/10.1073/pnas.0712363105.
33. Stanley SK, Ostrowski MA, Justement JS, Gantt K, Hedayati S, Mannix M, et al. Effect of immunization with a common recall antigen on viral expression in patients infected with human immunodeficiency virus type 1. N Engl J Med 1996; 334:1222-30; PMID:8606717; http://dx.doi.org/10.1056/NEJM199605093341903.
34. Staprans SI, Hamilton BL, Follansbee SE, Elbeik T, Barbosa P, Grant RM, et al. Activation of virus replication after vaccination of HIV-1-infected individuals. J Exp Med 1995; 182:1727-37; PMID:7500017; http://dx.doi.org/10. 1084/jem.182.6.1727.
35. Cohen SS, Li C, Ding L, Cao Y, Pardee AB, Shevach EM, et al. Pronounced acute immunosuppression in vivo mediated by HIV Tat challenge. Proc Natl Acad Sci USA 1999; 96:10842-7; PMID:10485913; http://dx.doi.org/10.1073/pnas.96.19. 10842.